Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

697
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
697

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mental Health Outcomes Among Long-Term Survivors of Childhood, Adolescent and Young Adult Cancer: A Scottish Population-Based Cohort Study.

Psycho-oncology·2026
Same author

Stress unmasks impaired endocrine coordination of glucose metabolism in dystrophin deficiency.

bioRxiv : the preprint server for biology·2026
Same author

Progressive Myopenia and Functional Decline in the Winnie Mouse Model of Chronic Colitis.

Muscles (Basel, Switzerland)·2026
Same author

Autologous macrophage therapy increases transplant-free survival in cirrhosis: Long-term follow-up of a phase 2 clinical trial.

Cell stem cell·2026
Same author

From bench to byte: A UK perspective on data-driven cancer research.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Single-Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same journal

Mechanistic constraints in dengue severity: a systematic review with evidence stratification and agent-based evaluation of logical sufficiency.

Frontiers in immunology·2026
Same journal

Circadian control of immune homeostasis in cardiovascular health and disease.

Frontiers in immunology·2026
Same journal

An IHC-derived TLS-CD8-macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC.

Frontiers in immunology·2026
Same journal

AF6 orchestrates macrophage polarization via JAK2-STAT3 signaling and supports intestinal regeneration by stimulating stem cell proliferation.

Frontiers in immunology·2026
Same journal

Restoring immune homeostasis in the spinal microenvironment: targeting mechano-inflammation and immunometabolic reprogramming.

Frontiers in immunology·2026
Same journal

A self-perpetuating neuron-intrinsic GSDMD-mtDNA-AIM2 inflammasome axis drives neuronal pyroptosis and cognitive impairment after traumatic brain injury.

Frontiers in immunology·2026
查看所有相关文章

相关实验视频

Updated: Jun 21, 2025

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

12.7K

通过选择产生的EBV T细胞免疫疗法与LCL刺激相比,增强了效应器功能.

Rachel S Cooper1,2, Catherine Sutherland3, Linda M Smith1

  • 1Tissues, Cells and Advanced Therapeutics, Scottish National Blood Transfusion Service, Jack Copland Centre, Heriot Watt Research Park, Edinburgh, United Kingdom.

Frontiers in immunology
|July 16, 2024
PubMed
概括
此摘要是机器生成的。

一种新的基于的方法快速制造埃普斯坦-巴尔病毒 (EBV) 特定的T细胞 (VST),用于治疗移植后淋巴增殖性疾病 (PTLD). 与传统方法相比,这种无病毒的方法产生了优异的T细胞记忆和更广泛的抗原特异性.

关键词:
爱斯坦-巴尔病毒病毒.一个T细胞细胞.T细胞受体受体的 T 细胞受体.细胞治疗疗法细胞治疗疗法免疫疗法 免疫疗法淋巴细胞细胞系的细胞系这是一种类.强度强度强度是什么意思

更多相关视频

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.2K
HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

15.4K

相关实验视频

Last Updated: Jun 21, 2025

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

12.7K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.2K
HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

15.4K

科学领域:

  • 免疫治疗是一种免疫疗法.
  • 病毒学 病毒学
  • 细胞生物学 细胞生物学

背景情况:

  • 使用埃普斯坦-巴尔病毒 (EBV) 特定T细胞的采用免疫疗法为EBV诱导的移植后淋巴增殖性疾病 (PTLD) 提供了有希望的治疗方法.
  • 传统的制造依赖于EBV转换的淋巴细胞细胞系 (LCLs),这是耗时的,昂贵的,并携带与活病毒暴露相关的风险.

研究的目的:

  • 为临床应用开发和描述一种新的基于的,无病毒的EBV特异性T细胞 (VST) 制造系统.
  • 为了比较衍生的VST与标准LCL衍生的VST的疗效和特征.

主要方法:

  • 开发了一种基于的,无病毒的,无血清的封闭系统,用于VST制造.
  • 利用多参数流细胞计,HLA匹配的全源细胞毒性测定和高通量T细胞受体-β (TCRβ) 测序进行全面的表征.
  • 评估了T细胞种群,耗尽标记,细胞毒性活性,细胞因子生产和T细胞受体谱.

主要成果:

  • 与LCL衍生的VST相比,基衍生的VST表现出扩大的中央记忆群体和减少疲劳标记的表达.
  • 这两种方法都显示了类似的EBV感染目标的特定杀死,但衍生的VST显示出显著更高的抗病毒细胞因子和脱粒标记表达.
  • 来自的VST在CD8+和CD4+T细胞区中对EBV核抗原 (EBNA) 显示出更广泛和增强的特异性.
  • 基于的方法允许快速制造和显著增加产品产量.

结论:

  • 基于的制造提供了一种更有效和潜在的更安全的替代方案,用于生产用于PTLD治疗的EBV特异性T细胞.
  • 衍生VST的增强特征,包括改进的记忆和更广泛的抗原向,可能会导致更好的临床结果.
  • 这种新的方法简化了VST的生产,使这种免疫疗法更容易获得复发或耐药PTLD的患者.